Wilbanks Smith & Thomas Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-85	Closed	-$2K	–	1537
2018 Q3	$2K	Buy	+85	New	+$1.62K	﹤0.01%	1471

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's HZNP Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 85 shares — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in HZNP in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

Wilbanks Smith & Thomas Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 85 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $2K.
Wilbanks Smith & Thomas Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2018 and held it in 1 quarter.
Wilbanks Smith & Thomas Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2K in Q3 2018.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.